<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541045</url>
  </required_header>
  <id_info>
    <org_study_id>DI/15/108/03/48</org_study_id>
    <nct_id>NCT02541045</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients&#xD;
      with biopsy-proven non-alcoholic steatohepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type and design of the study: A randomized, placebo-controlled, double-blind, clinical trial&#xD;
      to evaluate the efficacy of metadoxine as a therapy in patients with biopsy-proven&#xD;
      nonalcoholic steatohepatitis.&#xD;
&#xD;
      Population: Non-diabetic patients with nonalcoholic steatohepatitis diagnosed by liver biopsy&#xD;
      through the &quot;nonalcoholic fatty liver disease activity score&quot; (NAS)&gt; 3.&#xD;
&#xD;
      Sample size: Considering a difference of at least 30% between groups, a confidence level of&#xD;
      95% (two-sided, significance 0.05), a statistical power of 80%, and an additional 20% for&#xD;
      possible losses, we need 54 patients per group.&#xD;
&#xD;
      Variables:&#xD;
&#xD;
      Independent: Treatment group (metadoxine / placebo).&#xD;
&#xD;
      Dependents:&#xD;
&#xD;
        -  &quot;Nonalcoholic fatty liver disease activity score&quot; (NAS):0 a 8&#xD;
&#xD;
        -  Degree of liver steatosis: 0 a 3&#xD;
&#xD;
        -  Degree of lobular inflammation: 0 a 3&#xD;
&#xD;
        -  Degree of ballooning: 0 a 2&#xD;
&#xD;
        -  Degree of fibrosis: 0 a 2&#xD;
&#xD;
        -  Weight: Kg&#xD;
&#xD;
        -  Body mass index: Kg/m2&#xD;
&#xD;
        -  Waist circumference: cm&#xD;
&#xD;
        -  Serum alanine aminotransferase: U/L&#xD;
&#xD;
        -  Serum aspartate aminotransferase: U/L&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Those meeting the selection criteria will be invited to participate in this study, those who&#xD;
      agree to participate must sign the consent form and will be randomized to placebo or&#xD;
      metadoxine group. The duration of the therapy will be 6 months and after this period a second&#xD;
      liver biopsy will be performed to assessed the improvement on liver histology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    lack of resources to finance the project&#xD;
  </why_stopped>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in the degree of non-alcoholic fatty liver disease score (NAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Non-alcoholic fatty liver disease score (NAS) is an histological classification to assessed the severity of liver steatosis, lobular inflammation and ballooning in the liver biopsy. It is measured on a scale from 0 to 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in liver steatosis measured on a scale from 0 to 3</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in lobular inflammation measured on a scale from 0 to 3</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in ballooning measured on a scale from 0 to 2</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in alanine aminotransferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in aspartate aminotransferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in the degree of liver fibrosis measured on a scale from 0 to 2</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare the occurrence of adverse effects between groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Metadoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapy with metadoxine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metadoxine</intervention_name>
    <description>metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months</description>
    <arm_group_label>Group 2: Metadoxine</arm_group_label>
    <other_name>Abrixone, Metadoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets: 1 Tablet by mouth twice in day during 6 months</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-diabetic patients,&#xD;
&#xD;
          -  Overweight or with obesity degrees I, II or III according to WHO criteria (BMI ≥ 25),&#xD;
&#xD;
          -  With evidence of liver steatosis in the ultrasonography,&#xD;
&#xD;
          -  With biopsy-proven nonalcoholic steatohepatitis, with ≥ 3 in the NAS score (at least 1&#xD;
             point for liver steatosis, at least 1 point for lobular inflammation, and at least 1&#xD;
             point for ballooning),&#xD;
&#xD;
          -  With or without fibrosis in the liver biopsy, but if it is present must be ≤ 2 on a&#xD;
             scale of 4, where 4 is equivalent to cirrhosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis,&#xD;
&#xD;
          -  Diabetes,&#xD;
&#xD;
          -  Heavy alcohol intake ( ≥ 20 g / day), ≥ 8 points in the &quot;Alcohol Use Disorders&#xD;
             Identification Test&quot; (AUDIT),&#xD;
&#xD;
          -  Acute or chronic hepatitis C,&#xD;
&#xD;
          -  Acute or chronic hepatitis B,&#xD;
&#xD;
          -  Immunodeficiency acquired syndrome&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  In the last year, history of herbal consumption, total parenteral nutrition,&#xD;
             amiodarone, methotrexate, hormonal contraceptives, steroids, tamoxifen, valproic acid&#xD;
             or any other drug associated with the development of liver steatosis.&#xD;
&#xD;
          -  Uncontrolled hypothyroidism or hyperthyroidism,&#xD;
&#xD;
          -  Any uncontrolled chronic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatima Higuera-de la Tijera, MD, MSc.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General de México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de México</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>MARIA DE FATIMA HIGUERA DE LA TIJERA</investigator_full_name>
    <investigator_title>MD, MSc.</investigator_title>
  </responsible_party>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>metadoxine</keyword>
  <keyword>efficacy</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metadoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

